Table 2. Results of meta-analysis for XRCC1 and XRCC3 polymorphisms and lung cancer risk.
| Variables | No. comparisons (SZ case/control) | Dominant model | Recessive model | Additive model | |||
| OR (95% CI) | P h/I 2 | OR (95% CI) | P h/I 2 | OR (95% CI) | P h/I 2 | ||
| XRCC1 Arg399Gln | |||||||
| Overall | 41 (14,156/16,667) | 1.00 (0.94–1.07)* | 0.009/37.9% | 1.05 (0.94–1.18)* | 0.017/36.4% | 1.05 (0.93–1.19)* | 0.003/43.3% |
| Caucasian | 19 (7,308/9,140) | 0.98 (0.92–1.04) | 0.560/0.0% | 1.00 (0.87–1.16)* | 0.054/38.4% | 0.99 (0.89–1.10) | 0.120/29.7% |
| Asian | 19 (6,324/6,883) | 1.06 (0.94–1.20)* | <0.001/60.5% | 1.17 (0.96–1.41)* | 0.038/40.7% | 1.16 (0.93–1.46)* | 0.002/56.3% |
| African | 3 (524/644) | 1.04 (0.81–1.35) | 0.682/0.0% | 0.79 (0.39–1.62) | 0.603/0.0% | 0.80 (0.39–1.64) | 0.645/0.0% |
| PB | 18 (5,943/7,925) | 0.94 (0.87–1.01) | 0.116/29.5% | 1.01 (0.90–1.14) | 0.145/27.1% | 0.97 (0.86–1.10) | 0.119/29.8% |
| HB | 23 (8,213/8,742) | 1.07 (0.98–1.16)* | 0.062/33.4% | 1.15 (0.98–1.34)* | 0.015/44.7% | 1.17 (0.98–1.40)* | 0.004/50.9% |
| AC | 11 (1,821/5,536) | 1.13 (0.92–1.39)* | 0.002/64.4% | 1.31 (0.92–1.87)* | 0.001/66.7% | 1.34 (0.89–2.03)* | <0.001/73.3% |
| SC | 6 (1,688/4,014) | 0.97 (0.75–1.26)* | 0.006/69.4% | 1.06 (0.89–1.27) | 0.225/29.5% | 1.10 (0.77–1.57)* | 0.058/56.1% |
| SCLC | 3 (112/879) | 0.75 (0.37–1.55)* | 0.088/58.8% | 0.67 (0.32–1.43) | 0.642/0.0% | 0.62 (0.28–1.37) | 0.997/0.0% |
| Non-smokers | 15 (1,300/2,874) | 1.09 (0.83–1.43)* | 0.001/62.4% | 1.57 (1.02–2.42) * | 0.026/49.4% | 1.63 (0.99–2.68)* | 0.007/57.6% |
| Smokers | 16 (5,081/4,525) | 1.02 (0.94–1.11) | 0.536/0.0% | 1.02 (0.89–1.18) | 0.886/0.0% | 1.04 (0.89–1.21) | 0.743/0.0% |
| Male | 3 (441/414) | 1.08 (0.83–1.42) | 0.559/0.0% | 1.02 (0.39–4.31)* | 0.087/65.8% | 1.02 (0.60–1.72) | 0.159/49.7% |
| Female | 5 (773/826) | 0.96 (0.58–1.60)* | 0.001/78.1% | 1.94 (0.73–5.14)* | 0.014/71.8% | 1.86 (0.55–6.27)* | 0.001/80.6% |
| XRCC1 Arg194Trp | |||||||
| Overall | 23 (7,426/9,603) | 0.96 (0.86–1.07)* | 0.042/36.5% | 1.23 (1.05–1.44) | 0.216/18.8% | 1.22 (1.04–1.44) | 0.107/28.9% |
| Caucasian | 10 (3,926/5,639) | 0.88 (0.78–1.01) | 0.472/0.0% | 1.32 (0.78–2.23) | 0.104/41.2% | 1.29 (0.76–2.18) | 0.102/41.5% |
| Asian | 11 (3,091/3,441) | 1.02 (0.88–1.19)* | 0.065/42.6% | 1.22 (1.03–1.45) | 0.277/17.5% | 1.22 (1.02–1.45) | 0.111/36.0% |
| PB | 11 (2,610/4,446) | 0.98 (0.87–1.11) | 0.356/9.2% | 1.17 (0.93–1.49) | 0.359/9.1% | 1.16 (0.91–1.48) | 0.264/19.5% |
| HB | 12 (4,816/5,157) | 0.94 (0.80–1.11)* | 0.015/53.1% | 1.28 (1.03–1.59) | 0.141/32.2% | 1.29 (0.90–1.86)* | 0.077/40.8% |
| AC | 5 (880/3,276) | 0.97 (0.80–1.18) | 0.634/0.0% | 1.43 (0.86–2.40) | 0.587/0.0% | 1.41 (0.82–2.41) | 0.682/0.0% |
| SC | 3 (1,147/2,876) | 0.86 (0.70–1.05) | 0.850/0.0% | 1.38 (0.68–2.80) | 0.558/0.0% | 1.35 (0.63–2.88) | 0.554/0.0% |
| Non-smokers | 7 (618/1,666) | 1.07 (0.86–1.34) | 0.242/24.6% | 1.40 (0.38–5.17)* | 0.030/62.8% | 1.12 (0.26–4.79)* | 0.031/66.1% |
| Smokers | 6 (2,886/2,476) | 0.83 (0.71–0.98) | 0.141/39.7% | 0.93 (0.44–1.99) | 0.804/0.0% | 0.74 (0.30–1.85) | 0.681/0.0% |
| XRCC1 Arg280His | |||||||
| Overall | 16 (6,211/6,763) | 1.04 (0.83–1.29)* | <0.001/74.7% | 1.30 (0.71–2.37)* | 0.065/39.3% | 1.46 (0.99–2.15) | 0.146/29.0% |
| Caucasian | 9 (4,030/4,464) | 1.06 (0.92–1.22) | 0.133/35.6% | 0.96 (0.50–1.87) | 0.161/34.9% | 1.37 (0.68–2.78) | 0.721/0.0% |
| Asian | 7 (2,181/2,299) | 0.97 (0.64–1.48)* | <0.001/86.3% | 1.48 (0.68–3.21)* | 0.072/48.2% | 1.45 (0.60–3.48)* | 0.023/58.9% |
| PB | 7 (2,247/2,683) | 1.06 (0.90–1.23) | 0.334/12.5% | 1.32 (0.41–4.20)* | 0.048/52.9% | 1.43 (0.77–2.63) | 0.274/20.4% |
| HB | 9 (3,964/4,080) | 0.93 (0.64–1.35)* | <0.001/84.1% | 1.54 (0.94–2.51) | 0.244/24.2% | 1.32 (0.60–2.93)* | 0.097/44.1% |
| AC | 3 (795/2,864) | 0.70 (0.34–1.42)* | 0.001/85.5% | 0.36 (0.07–2.01) | – | 0.25 (0.04–1.39) | – |
| Non-smokers | 6 (715/1,340) | 0.63 (0.35–1.13)* | 0.001/74.7% | 0.78 (0.29–2.12) | 0.606/0.0% | 0.64 (0.23–1.75) | 0.380/0.0% |
| Smokers | 6 (2,977/2,457) | 1.04 (0.78–1.38) | 0.942/0.0% | 3.93 (0.44–35.3) | 0.820/0.0% | 4.16 (0.46–37.6) | 0.851/0.0% |
| XRCC1 −77T>C (rs3213245) | |||||||
| Overall | 5 (2,487/2,576) | 1.45 (1.27–1.66) | 0.638/0.0% | 1.73 (1.14–2.62) | 0.469/0.0% | 1.91 (1.24–2.94) | 0.494/0.0% |
| XRCC3 T241M (rs861539) | |||||||
| Overall | 19 (8,560/11,557) | 0.93 (0.83–1.04)* | 0.011/48.8% | 1.09 (0.88–1.35)* | 0.003/56.8% | 1.06 (0.83–1.37)* | <0.001//65.5% |
| Caucasian | 12 (6,089/8,992) | 0.92 (0.80–1.06)* | 0.003/60.6% | 1.07 (0.84–1.36)* | 0.001/67.6% | 1.04 (0.79–1.37)* | <0.001/72.5% |
| Asian | 5 (2,201/2,141) | 0.96 (0.78–1.18) | 0.447/0.0% | 1.20 (0.60–2.39) | 0.504/0.0% | 1.18 (0.54–2.55) | 0.302/16.5% |
| PB | 8 (1,528/2,950) | 0.91 (0.79–1.04) | 0.623/0.0% | 0.95 (0.75–1.20) | 0.820/0.0% | 0.93 (0.73–1.19) | 0.775/0.0% |
| HB | 11 (7,032/8,607) | 0.96 (0.80–1.14)* | 0.002/66.1% | 1.25 (0.88–1.77)* | <0.001/72.3% | 1.22 (0.81–1.85)* | <0.001/78.6% |
| Smokers | 5 (698/756) | 0.83 (0.67–1.03) | 0.137/42.8% | 1.32 (0.81–2.14) | 0.749/0.0% | 1.22 (0.74–2.01) | 0.822/0.0% |
AC Adenocarcinoma, SC Squamous cell carcinoma, SCLC Small cell lung cancer,
*
Random-effect model was used when P value of heterogeneity test (P h)<0.10; otherwise, fixed-effect model was used.